ESC 365 - The SGLT2 inhibitor empagliflozin in patients hospitalised for acute heart failure: a multinational randomised trial

ESC Professional Premium Access

The SGLT2 inhibitor empagliflozin in patients hospitalised for acute heart failure: a multinational randomised trial

Session: Nature Medicine: highlights in cardiovascular research

Topic: Chronic Heart Failure

Speaker: Professor C. Angermann (Wurzburg, DE)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor Christiane E Angermann

University Hospital of Wurzburg, Wurzburg (Germany)

15 presentations

1 follower

3 more presentations in this session

RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in serum triglyceride and non-HDL cholesterol concentrations: first human results with ARO-ANG3

Speaker: Professor G. Watts (Perth, AU)

Long-term cardiac pathology in individuals with mild initial COVID-19 illness

Speaker: Doctor V. Puntmann (Frankfurt, DE)

Machine learning for diagnosis of myocardial infarction using cardiac troponin concentrations

Speaker: Doctor D. Doudesis (Edinburgh, GB)

Access the full session

Nature Medicine: highlights in cardiovascular research

Speakers: Professor C. Angermann, Professor G. Watts, Doctor V. Puntmann, Doctor D. Doudesis

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources